These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22171470)

  • 21. Apnea with RSV infection in three infants receiving palivizumab.
    Del Vecchio MT
    Pediatr Int; 2013 Dec; 55(6):e159-61. PubMed ID: 24330303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
    Both L; Banyard AC; van Dolleweerd C; Wright E; Ma JK; Fooks AR
    Vaccine; 2013 Mar; 31(12):1553-9. PubMed ID: 23370150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 25. [Monoclonal antibodies in diseases of viral origin].
    Aguilar Setién A; Kretschmer R
    Salud Publica Mex; 1985; 27(3):251-9. PubMed ID: 2996158
    [No Abstract]   [Full Text] [Related]  

  • 26. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab.
    Resch B; Michel-Behnke I
    Curr Opin Cardiol; 2013 Mar; 28(2):85-91. PubMed ID: 23337892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.
    Bauman J; Eggleston M; Oquist N; Malinoski F
    South Med J; 2007 Jul; 100(7):669-76. PubMed ID: 17639745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?
    Elnazir B; Oni O; Hassan T; Greally P; Paes B
    J Paediatr Child Health; 2012 Nov; 48(11):1033-8. PubMed ID: 23126393
    [No Abstract]   [Full Text] [Related]  

  • 29. Palivizumab.
    Gupta D; Gupta P
    Indian Pediatr; 2001 Nov; 38(11):1265-9. PubMed ID: 11721066
    [No Abstract]   [Full Text] [Related]  

  • 30. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palivizumab use in Japanese infants and children with immunocompromised conditions.
    Mori M; Onodera M; Morimoto A; Kosaka Y; Morio T; Notario GF; Sharma S; Saji T
    Pediatr Infect Dis J; 2014 Nov; 33(11):1183-5. PubMed ID: 24830698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New perspectives in Respiratory Syncitial Virus infection.
    Del Vecchio A; Ferrara T; Maglione M; Capasso L; Raimondi F
    J Matern Fetal Neonatal Med; 2013 Oct; 26 Suppl 2():55-9. PubMed ID: 24059554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Review of the recent advances on interferon and interferon therapy].
    Doğanay M
    Mikrobiyol Bul; 1983 Jan; 17(1):69-73. PubMed ID: 6193401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention and treatment of respiratory syncytial virus infections (for advances in pediatric infectious diseases).
    DeVincenzo J
    Adv Pediatr Infect Dis; 1997; 13():1-47. PubMed ID: 9544306
    [No Abstract]   [Full Text] [Related]  

  • 35. [Palivizumab for respiratory syncytial virus disease].
    Carrera G; D'alterio R; Leone G; Zambetti C
    Minerva Pediatr; 2013 Oct; 65(5):505-12. PubMed ID: 24056377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palivizumab and RSV prevention.
    Carnegie C
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960341
    [No Abstract]   [Full Text] [Related]  

  • 37. Palivizumab and RSV prevention.
    Lenney W
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960342
    [No Abstract]   [Full Text] [Related]  

  • 38. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases.
    Chanock RM; Crowe JE; Murphy BR; Burton DR
    Infect Agents Dis; 1993 Jun; 2(3):118-31. PubMed ID: 8173784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palivizumab. An example of indication creep.
    Isaacs D
    BMJ; 2009 Jul; 339():b2724. PubMed ID: 19581330
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.